RECOMBINANT SALMONELLA AS AN ORAL HIV VACCINE

Project: Research project

Project Details

Description

This study investigates the feasibility of using live attenuated
Salmonella as an oral vaccine vector for the delivery of human
immunodeficiency virus antigens. Salmonella is promising as a candidate
vaccine vector for several reasons. First, this organism elicits both
systemic and mucosal immune responses. As most cases of HIV are sexually
transmitted, mucosal immunity is likely to be critical in preventing
infection. Second, foreign genes cloned into attenuated Salmonella vaccine
strains have already been shown to elicit immune responses to viral,
bacterial, fungal, and parasitic antigens in animal models. Third, an
orally administered vaccine offers praCtical and financial advantages over
parenterally administered vaccines. The primary objective of this study is to develop a strain of attenuated
Salmonella stably expressing the HIV-1 gpl20 envelope protein. The
candidate vaccine will be administered orally to BALB/c mice, and assessed
for its ability to elicit humoral and cellular immune responses in both
the systemic and mucosal compartments. The secondary objective is to
delineate variables of antigen expression (such as plasmid copy number,
mode of foreign gene regulation) important in the host immune response to
Salmonella. The third objective of this project is to address the areas of
oral Salmonella vaccine technology, and mucosal immunity, about which
little is known. Such knowledge has potential for widespread application
beyond the realm of HIV prevention.
StatusFinished
Effective start/end date9/1/948/31/98

Funding

  • National Institutes of Health: $95,181.00
  • National Institutes of Health: $95,085.00
  • National Institutes of Health: $95,085.00

ASJC

  • Medicine(all)
  • Immunology and Microbiology(all)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.